Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma.

Abstract:

INTRODUCTION:Hodgkin's lymphoma (HL) is largely a curable disease with excellent prognosis. The standard of care in patients with relapsed disease has been to try salvage chemotherapy followed by an autologous stem cell transplantation (ASCT). Managing the patients who relapse after ASCT, is challenging. With the approval of targeted therapies such as PD-1 inhibitors, brentuximab vedotin, the outcomes have improved greatly. Areas covered: This review summarizes the current data available on the newer therapies as well as the present strategies used to treat patients with relapsed HL after an autologous stem cell transplantation. Expert commentary: The approval of brentuximab vedotin and PD-L1 inhibitors has ushered in a new era of targeted therapy in HL. There are currently several targeted therapies under investigation, particularly in the setting of relapsed disease. The current challenges faced are how best to integrate these newer therapies into the existing treatment regimens, finding a right combination with minimal toxicities, role of allogenic transplant in the era of targeted therapy.

journal_name

Expert Rev Hematol

authors

Kallam A,Armitage JO

doi

10.1080/17474086.2018.1449637

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

293-300

issue

4

eissn

1747-4086

issn

1747-4094

journal_volume

11

pub_type

杂志文章,评审
  • FLT3 inhibitors in acute myeloid leukemia.

    abstract::The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute myeloid leukemias (AMLs) and are associated with a distinctly poor clinical outcome for patients. There are now several class...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.1.2.153

    authors: el-Shami K,Stone RM,Smith BD

    更新日期:2008-12-01 00:00:00

  • Gonadal dysfunction in adult male patients with thalassemia major: an update for clinicians caring for thalassemia.

    abstract:INTRODUCTION:Hypogonadism is the most frequently reported endocrine complication, affecting 40%-80% of thalassemia major (TM) patients. The prevalence and severity of hypogonadism in TM varies among studies, depending on patients' age, genotype, transfusion frequency and starting age and efficiency of iron chelation. A...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1398080

    authors: De Sanctis V,Soliman AT,Elsedfy H,Di Maio S,Canatan D,Soliman N,Karimi M,Kattamis C

    更新日期:2017-12-01 00:00:00

  • Transfusion strategies in patients undergoing stem-cell transplantation.

    abstract::Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.14

    authors: Radia R,Pamphilon D

    更新日期:2011-04-01 00:00:00

  • Lestaurtinib: a multi-targeted FLT3 inhibitor.

    abstract::Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2.1.17

    authors: Fathi AT,Levis M

    更新日期:2009-02-01 00:00:00

  • Thrombocytopenia in neonates with polycythemia: incidence, risk factors and clinical outcome.

    abstract:BACKGROUND:Polycythemia occurs in 1 to 5% of neonates and is associated with complications, including an increased risk of thrombocytopenia. OBJECTIVE:To evaluate incidence, risk factors, management and outcome of thrombocytopenia in neonates with polycythemia. STUDY DESIGN:All neonates with polycythemia admitted to ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/17474086.2015.997705

    authors: Vlug RD,Lopriore E,Janssen M,Middeldorp JM,Rath ME,Smits-Wintjens VE

    更新日期:2015-02-01 00:00:00

  • Polyphosphates: a link between platelet activation, intrinsic coagulation and inflammation?

    abstract::Early evidence has already shown that activated platelets play a role in the intrinsic pathway of coagulation, but the mechanism remained unclear. The finding that the dense granules of platelets contain polyphosphate (polyP), which has procoagulant effects, resolved this missing link between activated platelets and c...

    journal_title:Expert review of hematology

    pub_type: 评论,杂志文章

    doi:10.1586/ehm.10.26

    authors: van der Meijden PE,Heemskerk JW

    更新日期:2010-06-01 00:00:00

  • Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.

    abstract::The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.7

    authors: Ninan MJ,Morrison VA

    更新日期:2009-04-01 00:00:00

  • Treatment of hairy cell leukemia.

    abstract:INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1819231

    authors: Chihara D,Kreitman RJ

    更新日期:2020-10-01 00:00:00

  • Position paper on management of iron deficiency in adult cancer patients.

    abstract:INTRODUCTION:Disorders of iron metabolism are commonly seen in onco-hematological clinical practice. Iron-deficiency anemia and cancer-associated anemia are usually treated with supportive therapies. Optimal management of these conditions are discussed in this perspective paper. Areas covered: A position paper discussi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2017.1343140

    authors: Barni S,Gascòn P,Petrelli F,García-Erce JA,Pedrazzoli P,Rosti G,Giordano G,Mafodda A,Múñoz M

    更新日期:2017-08-01 00:00:00

  • Mobilization of hematopoietic stem cells into the peripheral blood.

    abstract::Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.54

    authors: Damon LE,Damon LE

    更新日期:2009-12-01 00:00:00

  • T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?

    abstract::Introduction: Severe sickle cell disease is associated with progressive end-organ damage and early mortality in adults. While allogeneic hematopoietic cell transplant from a matched related donor is curative, the vast majority of patients do not have a compatible sibling. Accordingly, platforms using haploidentical do...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1642103

    authors: Patel DA,Akinsete AM,Connelly JA,Kassim AA

    更新日期:2019-09-01 00:00:00

  • Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.

    abstract:INTRODUCTION:Large granular lymphocytic leukemia (LGLL) is a low grade lymphoproliferative disorder characterized by the clonal proliferation of large granular lymphocytes (LGL) and recognised by the WHO. The diagnosis and management of these patients is challenging due to the limited information from prospective studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1284585

    authors: Matutes E

    更新日期:2017-03-01 00:00:00

  • Prognostic factors for multiple myeloma in the era of novel therapies.

    abstract:INTRODUCTION:Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retain...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2018.1537776

    authors: Ziogas DC,Dimopoulos MA,Kastritis E

    更新日期:2018-11-01 00:00:00

  • Transfusion medicine in trauma patients: an update.

    abstract::In 2008, we reviewed the practical interface between transfusion medicine and the surgery and critical care of severely injured patients. Reviewed topics ranged from epidemiology of trauma to patterns of resuscitation to the problems of transfusion reactions. In the interim, trauma specialists have adopted damage cont...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.49

    authors: Murthi SB,Stansbury LG,Dutton RP,Edelman BB,Scalea TM,Hess JR

    更新日期:2011-10-01 00:00:00

  • Andexanet alfa for the treatment of hemorrhage.

    abstract:INTRODUCTION:While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1532287

    authors: Cervi A,Crowther M

    更新日期:2018-11-01 00:00:00

  • Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease.

    abstract:OBJECTIVES:We analyzed hemoglobin (Hb) levels and degree of anemia in relation to genotype in patients with hemoglobin H (Hb H) disease, thereby providing a scientific basis for the prevention and treatment of Hb H disease in the Guangxi region of China. METHODS:Hb analysis was conducted in 615 patients using high per...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1803736

    authors: Luo S,Chen X,Chen L,Zhong Q,Wang Q,Xu Z,Huang J,Yan T,Tang N

    更新日期:2020-09-01 00:00:00

  • An update on biology, diagnosis and treatment of primary plasma cell leukemia.

    abstract:INTRODUCTION:Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendati...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1598258

    authors: Musto P,Statuto T,Valvano L,Grieco V,Nozza F,Vona G,Bochicchio GB,La Rocca F,D'Auria F

    更新日期:2019-04-01 00:00:00

  • Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.

    abstract::Tumor lysis syndrome (TLS) is a rare but potentially life-threatening complication of neoplasms, preferentially hematological malignancies. Well known since at least ninety years ago, this condition can be misdiagnosed and incorrectly managed due to rapid onset of symptoms, sometimes overlapping with cancer-derived cl...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1127156

    authors: Criscuolo M,Fianchi L,Dragonetti G,Pagano L

    更新日期:2016-01-01 00:00:00

  • Prognostic tools in follicular lymphomas.

    abstract::Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.34

    authors: Luminari S,Cox MC,Montanini A,Federico M

    更新日期:2009-10-01 00:00:00

  • Diagnosis and management of factor V Leiden.

    abstract:INTRODUCTION:The discovery of the factor V Leiden (FVL) missense mutation (Arg506Gln) causing factor V resistance to the anticoagulant action of activated protein C was a landmark that allowed a better understanding of the basis of inherited thrombotic risk. FVL mutation is currently the most common known hereditary de...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1249364

    authors: Campello E,Spiezia L,Simioni P

    更新日期:2016-12-01 00:00:00

  • Initial treatment of transplant-ineligible patients in multiple myeloma.

    abstract::Over two-thirds of newly diagnosed multiple myeloma are over 65 years. The treatment goals for the non-transplant-eligible patients should be to prolong survival by achieving the best response, while ensuring quality of life. New upfront treatment combinations based on first generation of novel proteasome inhibitors a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.864230

    authors: Mateos MV,Leleu X,Palumbo A,San Miguel JF

    更新日期:2014-02-01 00:00:00

  • The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

    abstract:INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1437345

    authors: Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

    更新日期:2018-03-01 00:00:00

  • Safety issues and management of toxicities associated with new treatments for multiple myeloma.

    abstract:INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2017.1284584

    authors: Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

    更新日期:2017-03-01 00:00:00

  • Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.

    abstract::Introduction: Secondary central nervous system lymphoma (SCNSL) is a potentially fatal event in the setting of aggressive Non-Hodgkin Lymphomas. Nowadays, despite of the very poor outcome of SCNSL, several studies are going to identify the high-risk patients' subgroup that could early develop this detrimental event an...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1643232

    authors: Santambrogio E,Nicolosi M,Vassallo F,Castellino A,Novo M,Chiappella A,Vitolo U

    更新日期:2019-09-01 00:00:00

  • Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.

    abstract::Sickle cell disease (SCD) is a severe genetic disorder of hemoglobin causing vaso-occlusion. Patients suffer severe anemia, strokes, renal failure, pulmonary compromise and shortened life expectancy. Over 90,000 people in the USA have SCD, and the options for therapy are limited and only partially effective. With the ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.12.20

    authors: Okam MM,Ebert BL

    更新日期:2012-06-01 00:00:00

  • Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.

    abstract::Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukem...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1144469

    authors: Hou HA,Tien HF

    更新日期:2016-05-01 00:00:00

  • Role of carfilzomib in the treatment of multiple myeloma.

    abstract::The introduction of bortezomib, a first-generation proteasome inhibitor, changed the standard-of-care for newly diagnosed and relapsed multiple myeloma patients. The next generation of proteasome inhibitors, such as carfilzomib, provides a novel pharmacokinetic and pharmacodynamic profile. In vitro data suggest a more...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.12.26

    authors: Khan RZ,Badros A

    更新日期:2012-08-01 00:00:00

  • Current options to manage Waldenström's macroglobulinemia.

    abstract:INTRODUCTION:Waldenström's macroglobulinemia (WM) is a rare, incurable B-cell lymphoma, with a median survival of 5-10 years in symptomatic patients. There is no consensus on the standard of care and several agents are currently used in these patients. Areas covered: In this article, we will review the use of standard ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1339596

    authors: Benevolo G,Nicolosi M,Santambrogio E,Vitolo U

    更新日期:2017-07-01 00:00:00

  • The gut microbiota - a modulator of endothelial cell function and a contributing environmental factor to arterial thrombosis.

    abstract::Introduction: There is emerging evidence linking the commensal gut microbiota with the development of cardiovascular disease and arterial thrombosis. In immunothrombosis, the host clotting system protects against the dissemination of invading microbes, not considering the huge number of microbes that interact with hos...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1627191

    authors: Formes H,Reinhardt C

    更新日期:2019-07-01 00:00:00

  • Ofatumumab for the treatment of chronic lymphocytic leukemia.

    abstract::Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1037736

    authors: Grosicki S

    更新日期:2015-06-01 00:00:00